Editas Medicine and Bristol Myers Squibb announced a collaboration on June 27, 2025, to develop new therapies together.
1 report, 0 independent
Updated Jun 27
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Editas Medicine and Bristol Myers Squibb announced a collaboration on June 27, 2025, to develop new therapies together.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
-
Editas Medicine
discovery-phase pharmaceutical company
Nothing else this week.
-
Bristol-Myers Squibb
American pharmaceutical company
Related events
- Bristol-Myers Squibb and AstraZeneca announced a collaboration on advanced cancer drug development.
- Bristol-Myers Squibb has taken ownership of Celgene's drug.
- Cocrystal Pharma and Bristol-Myers Squibb are competing for investment as healthcare companies.
- The FDA received information on June 27, 2025, regarding regulatory approval to streamline patient monitoring for a product involving Bristol-Myers Squibb.
- Bristol-Myers Squibb and Johnson & Johnson are both companies that are currently targets of LB Pharmaceuticals.
Coverage
Newest first; wire copies grouped- Unknown outlet